Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon
The Spectranetics Corp. · Decision date Nov 24, 2025
What did the FDA approve?
FDA records P160049/S027 as a supplement to PMA P160049, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 24, 2025.
FDA approval order statement
for the implementation of an alternative paclitaxel active pharmaceutical ingredient utilized in the drug coating of the Stellarex 0.035" OTW Drug-coated Angioplasty Balloon
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 24, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P160049/S027
- Regulatory pathway
- PMA supplement
- Applicant
- The Spectranetics Corp.
- Product code
- ONU
- Decision code
- APPR
- Decision date
- Nov 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.
- Applicant
- The Spectranetics Corp.
- Product code
- ONU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160049/S027 received
Application receipt date recorded by FDA.
P160049/S027 · FDA decision
Normal 180 Day Track
P160049/S028 · Related supplement
Stellarex 0.035 OTW Drug-Coated Angioplasty Balloon
Timeline entries are records held by MedtechLedger for P160049. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160049
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| The Spectranetics Corp. | PMA supplement | Mar 19, 2026 | FDA |
Explore the linked device profile
Other records with product code ONU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA | |
Ranger Paclitaxel-Coated Balloon CatheterP190019/S043 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 4, 2026 | FDA |
Lutonix 035 Drug Coated Balloon CatheterP130024/S045 | Lutonix | PMA supplement | Jul 9, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | May 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
The Spectranetics Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6531 Dumbarton Cir., Fremont, CA, 94555
Sources and methodology
- Original FDA record: P160049/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
